DECRYPTION – While attention is focused on vaccines, laboratories and biotechs continue to research.
One of the future treatments for Covid could be French. The Nantes-based biotech Xenothera is in fact working on a drug based on polyclonal antibodies intended for patients with moderate Covid in order to avoid, in particular, a transfer to intensive care. The results of the phase 2 trials of XAV-19, a single-dose injection treatment, are expected to be available at the end of the month. Xenothera, which sold 30,000 doses to the French state, expects availability by the end of the year.
Despite the advances in vaccination across the world, the pressure is not easing in laboratories and biotechs to develop anti-Covid treatments. The arsenal is still very limited in the face of the virus. However, with the progression of the Delta variant and the probable appearance of new mutations in the coming months, treatments are essential to eradicate the pandemic.
At the end of August 2021, 318 treatments and vaccines were in phase 2 or 3 of clinical development, according to Statista.
This article is for subscribers only. You have 77% left to discover.
Pushing back the limits of science is also freedom.
Continue reading your article for € 1 for 2 months
Already subscribed? Log in